Dan H. Moore, PhD

---

Education

University of California, Santa Barbara, CA, B.A., 1963, Mathematics
University of California, Berkeley, CA, Ph.D., 1970, Biostatistics

---

Professional Experience

• 1977-present
  Consultant Faculty in Biostatistics, U.C. Berkeley
• 1987-1993
  Chairman, Melanoma Investigation Task Group, Lawrence Livermore National Laboratory, Livermore, California
• 1972-1993
  Biostatistician, Biomedical Sciences Division, University of California, Lawrence Livermore National Laboratory, Livermore, California.
• 1992-present
  Associate Adjunct Professor, Department of Epidemiology and Biostatistics, University of California San Francisco
• 1994-present
  Biostatistician, Research Institute, California Pacific Medical Center, San Francisco, California
• 1998-present
  Member, Comprehensive Cancer Center, University of California San Francisco
• 2000-present
  Member NCI review panel for Clinical Oncology (CONC)

---

Selected Publications

• Moore DH II, Epstein L, Reeder J, Wheeless L, Waldman FM. Interlaboratory variability in fluorescence in situ hybridization analysis. Cytometry 25:125-132, 1996.
• Moore DH II, Pallavicini M, Cher ML, Gray JW. A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles. Cytometry, 28(3):183-90, 1997.
• Moore DH 2nd; Patterson HW; Hatch F; Discher D; Schneider JS; Bennett D; Mendelsohn ML. Case-control study of malignant melanoma among employees of the Lawrence Livermore National Laboratory. Am J Ind Med 32(4):377-91, 1997.
• Moore DH II, Tucker JD, Jones IM, Langlois RG, Pleshanov P, Vorobtsova I, Jensen R. A study of the effects of exposure on cleanup workers at the Chernobyl nuclear reactor accident using multiple end points. Rad. Res. 148:463-475, 1997.
• Thor AD, Liu S, Moore DH, II, Edgerton S. Comparison of mitotic index, in vitro BRDU labeling and MIB-1 assays to quantitate proliferation in breast cancer J Clin Oncol 17, 470-77, 1999.
• Moore II DH, Tucker JD. Biological dosimetry of Chernobyl clean-up workers: Inclusion of age and smoking data provide improved radiation dose estimates. Radiat Res. 152:655-664, 1999.
• Waldman FM, DeVries S, Chew KL, Moore II DH, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Nat Cancer Inst 92:313-320, 2000.
• Goodson WH 3rd, Moore DH 2nd, Ljung BM, Chew K, Mayall B, Smith HS, Waldman FM. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat. Jan;59(2):113-23. 2000.
• Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (Tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18(18):3230-9, 2000.
• Thor AD, Edgerton SM, Liu S, Moore DH II, Kwiatkowski DF. Gelsolin a negative prognostic factor and effector of motility in erbB-2+ EGFR+ breast cancers. J National Cancer Inst. 2001.
• Liu S Edgerton SM Moore DH II Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7:1716-1723, 2001
• Miller RG, Moore DH II, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56:843-848, 2001.
• Miller RG, Moore DH, Dronsky V, et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. Neurological Sciences 191:127-132, 2001.
• Jackson CE, Rosenfeld J, Moore DH, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation is ALS/MND patients. Neurological Sciences 191:75-78, 2001.
• Hodgson G, Hager JA, Volik S, Wernick SHM, Moore D, Albertson DG, Pinkel D, Collins C, Hanahan D, Gray JW.Genome scanning with array CGH delineates regional alterations in murine islet carcinomas Nature Genetics 2001
• Miller RG, Mitchell JD, Moore DH.Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2001;(4):CD001447. Review.
• Zheng L, Moore DH, Meng ZH, Ljung BM, Gray JW, Dairkee SH. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res. 62:1000-3, 2002.
• Goodson WH 3rd, Moore DH 2nd. Causes of physician delay in the diagnosis of breast cancer. Arch Intern Med. 2002 Jun 24;162(12):1343-8.
• Wilhelm M,Veltman WM, Olshen AB, Jain AN, Moore DH, Presti JC, Kovacs G, Waldman FM. Array-based comparative genomic hygridization for the differential diagnosis of renal cell cancer. Cancer Res. 62(4):957-60, 2002.
• Moore DH 2nd. How useful are retrospective studies in evaluating therapeutic interventions? Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):3.
• Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol. 2002 Nov;34(11):1318-30.
• Goodson WH III, Moore DH II. Overall Clinical Breast Examination as a Factor in Delayed Diagnosis of Breast cancer. Arch Surg. 2002 Oct;137(10):1152-6.
• Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, Moore DH 2nd, Etzell J, Waldman FM. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol. 2002 Jun;33(6):628-31.
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002;(2):CD001447. Review.
• Waldman FM, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst. 92(4):313-20, 2002.
• Hightower JM, Moore D. Mercury levelsin high-end consumers of fish. Environ Health Perspect 111(4):1-5, 2003.
• Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH 2nd, Waldman F. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 19;95(22):1692-702, 2003.
• Whorton DM, Moore DH, Seward JP, Noonan KA, Mendelsohn ML. Cancer incidence rates among Lawrence Livermore National Laboratory (LLNL) employees: 1974-1997. American Journal of Industrial Medicine. 45(1), 24-33. 2004.
• Yount Garret, Solfvin Jerry, Moore Dan, Schlitz Marilyn, Reading Melissa, Aldape Ken and Qian Yifang. In vitro test of external Qigong. BMC Complementary and Alternative Medicine 4:5. 2004.
• Melisko M, Hassin F, Metzroth L, Moore D, Brown B, Patel K, Rugo R, TripathyD. Patient and Physician Attitudes toward Breast Cancer Clinical Trials *Developing Interventions Based on Understanding Barriers. Clinical Breast Cancer., 2004.
• Kosanke, S, Edgerton SM, Moore D 2nd, Yang X, Mason T, Alvarez K, Jones L, Kim A, Thor AD. Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. Comp. Med. 54:280-7, 2004.
• Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM. Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ.Clin Cancer Res. 10(15):5160-7, 2004.
• Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. Jul 19 BMC Genomics. 2004